185 related articles for article (PubMed ID: 32605193)
1. Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer.
Juliá EP; Mordoh J; Levy EM
Cells; 2020 Jun; 9(7):. PubMed ID: 32605193
[TBL] [Abstract][Full Text] [Related]
2. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
3. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
[TBL] [Abstract][Full Text] [Related]
4. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
6. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
7. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
[TBL] [Abstract][Full Text] [Related]
10. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
12. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
13. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells.
Wehner R; Löbel B; Bornhäuser M; Schäkel K; Cartellieri M; Bachmann M; Rieber EP; Schmitz M
Int J Cancer; 2009 Jan; 124(2):358-66. PubMed ID: 18942710
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
[TBL] [Abstract][Full Text] [Related]
16. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Eur J Immunol; 2015 Jun; 45(6):1783-93. PubMed ID: 25773885
[TBL] [Abstract][Full Text] [Related]
18. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation.
Pan PY; Gu P; Li Q; Xu D; Weber K; Chen SH
J Immunol; 2004 Apr; 172(8):4779-89. PubMed ID: 15067054
[TBL] [Abstract][Full Text] [Related]
19. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Lu H; Dietsch GN; Matthews MA; Yang Y; Ghanekar S; Inokuma M; Suni M; Maino VC; Henderson KE; Howbert JJ; Disis ML; Hershberg RM
Clin Cancer Res; 2012 Jan; 18(2):499-509. PubMed ID: 22128302
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]